Amyloid-β immunotherapy for Alzheimer's disease: The end of the beginning

Nature Reviews Neuroscience

Volumn 3, Issue 10, 2002, Pages 824-828

  Schenk, Dale ^a  

^a ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AN-1792; ANTIBODY; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT; VACCINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; MENINGOENCEPHALITIS; METHODOLOGY; MOUSE; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; MENINGOENCEPHALITIS; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; TREATMENT OUTCOME; VACCINES;

EID: 0036780877     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn938     Document Type: Article

References (23)

1. Senior, K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 1, 3 (2002).
2. Tanzi, R. E. et al. The gene defects responsible for familial Alzheimer's disease. Neurobiol. Dis. 3, 159-168 (1996).
3. Hardy, J. New insights into the genetics of Alzheimer's disease. Ann. Med. 28, 255-258 (1996).
4. Citron, M. et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases P-protein production. Nature 360, 672-674 (1992).
5. Citron, M. et al. Mutant presenilins of Alzheimer's disease increase production of 42 residue amyloid β-protein in both transfected cells and transgenic mice. Nature Med. 3, 67-72 (1997).
6. Suzuki, N. et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (P APP717) mutants. Science 264, 1336-1340 (1994).
7. Borchelt, D. R. et al. Familial Alzheimer's disease-linked presenilin I variants elevate AP1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013 (1996).
8. Scheuner, D. et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864-870 (1996).
9. Schenk D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
10. Janus, C. et al. A P peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982 (2000).
11. Morgan, D. et al. A P peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985 (2000).
12. Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B. & Wisniewski, T. Immunization with a non- toxic/nonfibrillar amyloid-P homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159, 439-447 (2001).
13. Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nature Med. 6, 916-919 (2000).
14. DeMattos, R. B. et al. Peripheral anti-AP antibody alters CNS and plasma Aβ clearance and decreases brain AP burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 8850-8855 (2001).
15. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M. & Holtzman, D. M. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267 (2002).
16. Dodart, J. C. et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nature Neurosci. 5, 452-457 (2002).
17. Solomon, B., Koppel, R., Hanan, E. & Katzav, T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer P-amyloid peptide. Proc. Natl Acad. Sci. USA 93, 452-455 (1996).
18. Solomon, B., Koppel, R., Frenkel, D. & Hanan-Aharon, E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl Acad. Sci. USA 94, 4109-4112 (1997).
19. Bacskai, B. et al. Non-Fc mediated mechanisms are involved in clearance of amyloid-P in vivo by immunotherapy. J. Neurosci. 22, 7862-7872 (2002).
20. Frenkel, D., Katz, O. & Solomon, B. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl Acad. Sci. USA 97, 11455-11459 (2000).
21. Lopez, J. C. The comeback of immunization. Nature Rev Neurosci. 3, 330 (2002).
22. Hock, C. Vaccination therapy for Alzheimer's disease. Neurobiol. Aging 23, S143 (2002).
23. Monsonego, A. et al. Immunogenic aspects of amyloid β-peptide: implications for pathogenesis and treatment of Alzheimer's disease Neurobiol. Aging 23, S112 (2002).